Maurits P A van Meer1, Ramona Mögling2, Janienne Klaasse2, Felicity D Chandler2, Suzan D Pas2, Annemiek A van der Eijk2, Marion P G Koopmans2, Chantal B E M Reusken2, Corine H GeurtsvanKessel3. 1. Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: m.p.a.vanmeer@erasmusmc.nl. 2. Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: c.geurtsvankessel@erasmusmc.nl.
Abstract
BACKGROUND: Diagnostic requests for both Zika virus (ZIKV) and dengue virus (DENV) infections in returning travelers have significantly increased during the recent ZIKV outbreak in the Americás. These flaviviruses have overlapping clinical syndromes and geographical distribution, but diagnostic differentiation is important because of different clinical consequences. As flaviviruses are known to have a short viremic period, diagnostics often rely on serological methods, which are challenging due to extensive cross-reactive antibodies. OBJECTIVE: To re-evaluate the performance of DENV serological assays in laboratory confirmed ZIKV-infected travelers. STUDY DESIGN: The extent of cross-reactivity of the DENV NS1 antigen, IgM and IgG ELISA was analyzed in 152 clinical blood samples collected from 69 qRT-PCR and 24 virus neutralization titer (VNT) confirmed ZIKV-infected travelers. RESULTS: The majority of travelers in the presented cohort returned to the Netherlands from Suriname and presented with symptoms of fever and rash. Twenty-three percent of the female travelers were pregnant. None of the 39 ZIKV RNA positive blood samples were cross-reactive in the DENV NS1 antigen ELISA. The rates of cross-reactivity of the DENV IgM and IgG ELISÁs were 31% and 54%, respectively, after excluding travelers with (potential) previous DENV exposure. CONCLUSIONS: Although the DENV NS1 antigen assay was highly specific in this cohort of laboratory confirmed ZIKV-infected travelers, we demonstrate high percentages of cross-reactivity of DENV IgM and IgG ELISÁs of which diagnostic laboratories should be aware. In addition, the high rate of DENV IgG background of >25% complicates a proper serological diagnosis in this group.
BACKGROUND: Diagnostic requests for both Zika virus (ZIKV) and dengue virus (DENV) infections in returning travelers have significantly increased during the recent ZIKV outbreak in the Americás. These flaviviruses have overlapping clinical syndromes and geographical distribution, but diagnostic differentiation is important because of different clinical consequences. As flaviviruses are known to have a short viremic period, diagnostics often rely on serological methods, which are challenging due to extensive cross-reactive antibodies. OBJECTIVE: To re-evaluate the performance of DENV serological assays in laboratory confirmed ZIKV-infected travelers. STUDY DESIGN: The extent of cross-reactivity of the DENV NS1 antigen, IgM and IgG ELISA was analyzed in 152 clinical blood samples collected from 69 qRT-PCR and 24 virus neutralization titer (VNT) confirmed ZIKV-infected travelers. RESULTS: The majority of travelers in the presented cohort returned to the Netherlands from Suriname and presented with symptoms of fever and rash. Twenty-three percent of the female travelers were pregnant. None of the 39 ZIKV RNA positive blood samples were cross-reactive in the DENV NS1 antigen ELISA. The rates of cross-reactivity of the DENV IgM and IgG ELISÁs were 31% and 54%, respectively, after excluding travelers with (potential) previous DENV exposure. CONCLUSIONS: Although the DENV NS1 antigen assay was highly specific in this cohort of laboratory confirmed ZIKV-infected travelers, we demonstrate high percentages of cross-reactivity of DENV IgM and IgG ELISÁs of which diagnostic laboratories should be aware. In addition, the high rate of DENV IgG background of >25% complicates a proper serological diagnosis in this group.
Authors: Jasmine Tyson; Wen-Yang Tsai; Jih-Jin Tsai; Carlos Brites; Ludvig Mässgård; Han Ha Youn; Celia Pedroso; Jan Felix Drexler; Susan L Stramer; Angel Balmaseda; Eva Harris; Wei-Kung Wang Journal: J Clin Microbiol Date: 2019-01-30 Impact factor: 5.948
Authors: Alice F Versiani; Estefânia M N Martins; Lidia M Andrade; Laura Cox; Glauco C Pereira; Edel F Barbosa-Stancioli; Mauricio L Nogueira; Luiz O Ladeira; Flávio G da Fonseca Journal: Sci Rep Date: 2020-07-09 Impact factor: 4.379
Authors: Francesca Falconi-Agapito; Karen Kerkhof; Xiomara Merino; Johan Michiels; Marjan Van Esbroeck; Koen Bartholomeeusen; Michael Talledo; Kevin K Ariën Journal: Front Immunol Date: 2021-07-05 Impact factor: 7.561
Authors: Tereza Magalhaes; Cynthia Braga; Marli T Cordeiro; Andre L S Oliveira; Priscila M S Castanha; Ana Paula R Maciel; Nathalia M L Amancio; Pollyanne N Gouveia; Valter J Peixoto-da-Silva; Thaciana F L Peixoto; Helena Britto; Priscilla V Lima; Andreza R S Lima; Kerstin D Rosenberger; Thomas Jaenisch; Ernesto T A Marques Journal: PLoS Negl Trop Dis Date: 2017-11-06
Authors: Alexandra Rockstroh; Beyene Moges; Luisa Barzon; Alessandro Sinigaglia; Giorgio Palù; Widuranga Kumbukgolla; Jonas Schmidt-Chanasit; Manoel Sarno; Carlos Brites; Andres Moreira-Soto; Jan Felix Drexler; Orlando C Ferreira; Sebastian Ulbert Journal: Emerg Microbes Infect Date: 2017-11-08 Impact factor: 7.163
Authors: Corine H GeurtsvanKessel; Zhahirul Islam; Md Badrul Islam; Sandra Kamga; Nowshin Papri; David A M C van de Vijver; Chantal Reusken; Ramona Mogling; Astrid P Heikema; Israt Jahan; Florence K Pradel; Rebecca L Pavlicek; Quazi D Mohammad; Marion P G Koopmans; Bart C Jacobs; Hubert P Endtz Journal: Ann Clin Transl Neurol Date: 2018-04-06 Impact factor: 4.511
Authors: Emma J Quinn; Allena H-C Cheong; Julie K Calvert; Geoffrey Higgins; Trish Hahesy; David L Gordon; Jillian M Carr Journal: Trop Med Infect Dis Date: 2018-01-07